IP Library Granted Patent US 10,596,201
Granted Patent B2
US 10,596,201 · App. 16/121,969 · Granted Mar 24, 2020

Delipidated, decellularized adipose tissue matrix

Inventors: Yen-Chen Huang (East Brunswick, NJ); Asia Ivery (Hammond Plains, CA); Bryan Choi (San Marcos, CA); Benjamin Schilling (Pittsburgh, PA); Manh-Dan Ngo (Matawan, NJ)
Assignee: Musculoskeletal Transplant Foundation
A61K35/35A61L27/3604A61L27/3683A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,201
App. No.
16/121,969
Granted
Mar 24, 2020
Kind
B2
Abstract

An acellular soft tissue-derived matrix includes a collagenous tissue that has been delipidated and decellularized. Adipose tissue is among the soft tissues suitable for manufacturing an acellular soft tissue-derived matrix. Exogenous tissuegenic cells and other biologically-active factors may be added to the acellular matrix. The acellular matrix may be provided as particles, a slurry, a paste, a gel, or in some other form. The acellular matrix may be provided as a three-dimensional scaffold that has been reconstituted from particles of the three-dimensional tissue. The three-dimensional scaffold may have the shape of an anatomical feature and serve as a template for tissue repair or replacement. A method of making an acellular soft tissue-derived matrix includes steps of removing lipid from the soft tissue by solvent extraction and chemical decellularization of the soft tissue.

Claims (13)

1. A delipidated, decellularized adipose tissue matrix derived from a first sample of adipose tissue which has been delipidated prior to decellularizing, wherein the delipidated, decellularized adipose tissue matrix contains a first proportion of lipids which is less than a second proportion of lipids contained in a processed adipose tissue derived from a second sample of adipose tissue which has been decellularized prior to delipidating.

2. The matrix of claim 1 , wherein the delipidated, decellularized adipose tissue is substantially free of native cellular components.

3. The matrix of claim 1 , wherein the delipidated, decellularized adipose tissue matrix is substantially free of native nucleic acids.

4. The matrix of claim 1 , wherein the delipidated, decellularized adipose tissue matrix is substantially free of substances that pose a significant risk of causing an immunogenic response in a patient receiving said composition.

5. A composition, comprising the delipidated, decellularized adipose tissue matrix of claim 1 .

6. The composition of claim 5 , further comprising exogenous tissuegenic cells.

7. The composition of claim 6 , wherein said exogenous tissuegenic cells include exogenous stem cells.

8. The composition of claim 6 , wherein said exogenous tissuegenic cells include adipose-derived stem cells.

9. The composition of claim 5 , further comprising at least one exogenous growth-inductive substance.

10. The composition of claim 9 , wherein said at least one exogenous growth-inductive substance is selected from the group consisting of bone morphogenic proteins, vascular endothelial growth factor, basic fibroblast growth factor, transforming growth factor beta, platelet-derived growth factor, and neural epidermal growth-factor-like 1.

11. The composition of claim 5 , further comprising a carrier.

12. The composition of claim 11 , wherein said carrier includes a substance selected from the group consisting of an isotonic solution, a sodium chloride solution, lactated Ringer's solution, a phosphate-buffered saline solution, platelet rich plasma, hyaluronic acid, a derivative of hyaluronic acid, sodium hyaluronate, thrombin, fibrin, glycerin, collagen, lecithin, sugars, polysaccharides, and solutions thereof.

13. The composition of claim 11 , wherein said carrier includes a substance selected from the group consisting of polysaccharides, nucleic acids, carbohydrates, proteins, polypeptides, poly(α-hydroxy acids), poly(lactones), poly(amino acids), poly(anhydrides), poly(orthoesters), poly(anhydride-co-imides), poly(orthocarbonates), poly(α-hydroxy alkanoates), poly(dioxanones), poly(phosphoesters), poly(L-lactide) (PLLA), poly(D,L-lactide) (PDLLA), polyglycolide (PGA), poly(lactide-co-glycolide (PLGA), poly(L-lactide-co-D, L-lactide), poly(D,L-lactide-co-trimethylene carbonate), polyhydroxybutyrate (PHB), poly(ε-caprolactone), poly(δ-valerolactone), poly(γ-butyrolactone), poly(caprolactone), polyacrylic acid, polycarboxylic acid, poly(allylamine hydrochloride), poly(diallyldimethylammonium chloride), poly(ethyleneimine), polypropylene fumarate, polyvinyl alcohol, polyvinylpyrrolidone, polyethylene, polymethylmethacrylate, carbon fibers, poly(ethylene glycol), poly(ethylene oxide), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-polypropylene oxide) block copolymers, poly(ethylene terephthalate)polyamide, and copolymers thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2025
From: HUANG, YEN-CHEN; IVERY, ASIA; CHOI, BRYAN; SCHILLING, BENJAMIN; NGO, MANH-DAN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 072097/0352 →
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
SECURITY INTEREST Recorded Dec 23, 2020
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 054842/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2018
From: HUANG, YEN-CHEN; IVERY, ASIA; CHOI, BRYAN; SCHILLING, BENJAMIN; NGO, MANH-DAN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 046797/0380 →
Cited By (5)
US 12,383,246 US 12,447,180 US 12,629,453 US 12,636,408 US 12,697,414